CELFULL publishes first systematic NADH white paper on healthy longevity

CELFULL says it has released the world’s first systematic white paper on NADH research, technology and applications through NutraIngredients. The report and a new research collaboration program are meant to advance longevity science, improve NADH stability and delivery, and broaden access to standardized research materials.

Why it matters: - NADH research has been fragmented across science, formulation and application areas. - CELFULL says the new white paper gives researchers and industry a structured reference for evaluating NADH in healthy longevity work. - The publication also addresses a major barrier in the category: NADH instability during production, storage, transport and digestion. - Better stabilization and delivery could improve reproducibility in research and commercial use.

What happened: - CELFULL released what it calls the world’s first systematic white paper on NADH research, technology and applications through NutraIngredients. - The paper is titled "Celfull NADH & Healthy Longevity: Science, Stability & Delivery Innovation." - The release came from New York on Oct. 30, 2026. - CELFULL says the paper draws on years of aging research and technology development. - The company also introduced a global research collaboration program tied to the paper. - The white paper is available on NutraIngredients.

The details: - The paper focuses on cellular energy metabolism and the stabilization and delivery technologies needed to move research into practical applications. - CELFULL says the report consolidates dispersed findings into a framework covering the scientific basis of NADH, research evidence, stability challenges, delivery technologies and application advances. - The company says its work has expanded beyond NAD+ levels alone to study the NAD+/NADH redox system and the role of NADH, the reduced form of NAD+, in cellular energy metabolism. - CELFULL says NADH is sensitive to oxygen, light, moisture, temperature and acidic conditions. - The company says activity loss can occur during ingredient production, storage, transportation and passage through the stomach. - The white paper outlines an evaluation framework for NADH development and quality control. - CELFULL says its third-generation TurnA platform uses a four-layer coating to protect NADH in the stomach and enable targeted release in the intestine. - CELFULL says its fourth-generation Celfavor controlled-release microsphere technology builds on that platform to improve stability, protection, compatibility with other formulation ingredients and sustained release. - CELFULL says the paper presents results from the development and validation of those proprietary technologies.

Between the lines: - The white paper positions CELFULL as both a research publisher and a technology developer in longevity science. - Publishing through NutraIngredients gives the company a mainstream nutrition-industry channel for scientific visibility. - The collaboration program is also a practical move to lower the cost and friction of NADH studies by supplying stabilized ingredients and matching placebos. - CELFULL says the goal is to encourage independent evidence, not just internal validation.

What's next: - CELFULL says qualified academic and research teams can receive proprietary stabilized NADH microsphere ingredients and matching placebos free of charge. - The materials are intended for basic research, biological mechanism studies and translational studies. - The company says it wants to expand independent evidence on NADH mechanisms, potential applications and new research directions. - CELFULL says it will continue working on research cooperation, application standards and the technical foundations of healthy longevity.